Frantz EyeCare reports 98% of Light Adjustable Lens patients achieved refractive accuracy within ±0.50 D of target, exceeding published national cataract surgery benchmarks.
|Articles|May 5, 2003
Santen submits NDA for levofloxacin 1.5%
Santen Pharmaceuticals Co. filed a New Drug Application with the FDAon Monday for levofloxacin 1.5%, the company's new ocular anti-infectivedrug.The larger concentration of Levofloxacin is a potent, broad-spectrumantibiotic. The company reports that Levofloxacin's higher solubility, atneutral pH, allows the drug to be formulated at a higher concentration thanother fluoroquinolones on the market.
Advertisement
Advertisement
Related to this article
In this Q&A, Ping Moore, OD, covers emerging dry eye therapies, from selenium sulfide to next-gen cyclosporine, and how subtype-guided care shapes treatment choices.
Ophthalmology is projected to face one of the steepest physician shortages of any subspecialty by 2038.
Two investigational pipeline therapies take aim at the root causes of dry eye disease
Dry eye care pivots to root-cause diagnosis and personalized biologics/devices,
Cataract surgery becomes refractive: learn how IOL choices and preop counseling across distance, intermediate and near turn 20/20 into 20/happy.
Findings from the third annual State of Dry Eye survey link symptom management to quality of life gains, including lower anxiety and improved self-confidence.
June brings FDA clearance for Lumvoa, key retina and glaucoma trials, device deals, and hard truths on AI performance in eye care.
Advertisement
Advertisement
Trending on Eye Care Network - Ophthalmology Times
1
Retinal imaging as a window into atrial fibrillation
2
Comments from the FDA Advisory Committee meeting on SYD-101
3
OT Roundup: 3 FDA approvals, vorolanib insert miss, brepocitinib in uveitis
4
Lambert-Eaton Myasthenic Syndrome: how eye care professionals differentiate it from myasthenia gravis
5